<?xml version="1.0" encoding="UTF-8"?><ns2:project xmlns:ns1="http://gtr.rcuk.ac.uk/gtr/api" xmlns:ns2="http://gtr.rcuk.ac.uk/gtr/api/project" xmlns:ns3="http://gtr.rcuk.ac.uk/gtr/api/fund" xmlns:ns4="http://gtr.rcuk.ac.uk/gtr/api/person" xmlns:ns5="http://gtr.rcuk.ac.uk/gtr/api/project/outcome" xmlns:ns6="http://gtr.rcuk.ac.uk/gtr/api/organisation" ns1:created="2026-06-03T15:52:43Z" ns1:href="http://gtr.ukri.org/gtr/api/projects/F549821D-F151-4D34-A198-2DD0FBB83518" ns1:id="F549821D-F151-4D34-A198-2DD0FBB83518"><ns1:links><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/persons/FF334095-A6D2-479C-85FA-B0023A30F8AC" ns1:rel="PM_PER"/><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/organisations/93829F5F-A909-4E54-8401-732D46D86456" ns1:rel="LEAD_ORG"/><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/organisations/FE0AD965-17C1-4602-BF76-D6CDC97A387F" ns1:rel="PARTICIPANT_ORG"/><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/organisations/93829F5F-A909-4E54-8401-732D46D86456" ns1:rel="PARTICIPANT_ORG"/><ns1:link ns1:end="2023-06-29T23:00:00Z" ns1:href="http://gtr.ukri.org/gtr/api/funds/1F94734F-9ABE-42CF-9EB6-85B8F9E6EB71" ns1:rel="FUND" ns1:start="2021-06-30T23:00:00Z"/></ns1:links><ns2:identifiers><ns2:identifier ns2:type="RCUK">10000065</ns2:identifier></ns2:identifiers><ns2:title>Development of a child-friendly Continuous Glucose Monitor (CGM): A nanotechnological, minimally-invasive, transdermal sensor for the real-time and painless sensing of interstitial glucose for diabetes</ns2:title><ns2:status>Closed</ns2:status><ns2:grantCategory>Collaborative R&amp;D</ns2:grantCategory><ns2:leadFunder>Innovate UK</ns2:leadFunder><ns2:abstractText>Caura intends to develop a revolutionary child-friendly TRL8 real-time continuous glucose monitoring device (CGM) that addresses the main issues associated with current conventional CGM systems.

The cost of diabetes to healthcare systems has grown to &amp;pound;558bn globally (&amp;pound;9.8bn NHS) , with the majority of costs associated with the short-and long-term complications of abnormal glucose concentrations.

The sensor platform represents a step-change innovation in CGM technology, delivering a solution that is;

* Cheaper
* Near pain-free
* Highly accurate and provides real-time glucose monitoring with no blood draw.
* Can be utilised regularly by children and adults.

These disruptive innovations have significant potential and will result in a highly-effective CGM device for the NHS that both improves patient access, outcomes and reduces costs of CGM use x4.</ns2:abstractText></ns2:project>